ClinicalTrials.gov
public full text
Public Domain
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers#906667
- Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer#1250229
- Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC#875192
- Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1#892619
- Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy#1045866
Record · ID 1321016
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive